logo transparent gif
top_white_spacer
Home Latest Stock Forum Topics MyCorner - Personal Stocks Porfolio Stock Lists Investor Insights Investor Research & Links Dynamic Stock Charting FREE Registration About Us top spacer top spacer
 User Password Auto-Login
Enter Stock
 
righttip
branding

Back
First   < Newer   1621-1640 of 1738   Older>   Last  
Latest Forum Topics / Vicplas Intl    Last:0.08 --  Post Reply
Construction Material & Bio-Medical Outsourcing
wiltay
Master
30-Jul-2020 12:30     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		not bad... can break 0.135. hahaha thought maybe wait until FY reports    laugh
 Useful To Me  Not Useful To Me
wiltay
Master
29-Jul-2020 10:54     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		not bad.. quite stable between 130-135..   
 Useful To Me  Not Useful To Me


wiltay
Master
27-Jul-2020 17:44     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

https://www.straitstimes.com/business/companies-markets/xentiq-ip-and-what-it-means-to-own-the-product
 Useful To Me  Not Useful To Me
wiltay
Master
27-Jul-2020 17:37     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		The Board of Directors of Vicplas International Ltd (the &ldquo Company&rdquo , together with its subsidiaries, the &ldquo Group&rdquo ) wishes to announce that pursuant to a sale and purchase agreement made between the Company and the shareholders of XentiQ (Pte.) Ltd. (&ldquo XentiQ&rdquo ) on 24 July 2020, the Company has acquired an aggregate of 107,540 ordinary shares (the &ldquo Shares&rdquo ) in XentiQ, representing 19% of the share capital of XentiQ (the &ldquo Acquisition&rdquo ). XentiQ is a subsidiary of the Company incorporated in Singapore and its principal activity is in project design and engineering services. The Company holds 81% of the issued share capital of XentiQ prior to the Acquisition. The Acquisition will result in the Company increasing its ownership interest in XentiQ from 81% to 100%, thereby making XentiQ a wholly-owned subsidiary of the Company. This will allow the Company to have full control over the operation and corporate direction of XentiQ. The consideration of S$2.00 was arrived at on a willing-buyer and willing-seller basis, taking into consideration the unaudited net tangible assets attributable to the Shares (representing 19 per cent. of the issued share capital of XentiQ) of approximately negative S$170,000 as at 30 June 2020. The Acquisition is not expected to have a material impact on the net tangible assets or earnings per share of the Company for the current financial year ending 31 July 2020.   
 Useful To Me  Not Useful To Me
wiltay
Master
24-Jul-2020 08:52     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Ya.. 👍

Stockgod39      ( Date: 23-Jul-2020 22:13) Posted:

Forefront Medical is owned by Vicplas. Not to mention, demand to manufacture such tests will be there for a long, long time because the effectiveness of vaccines is not only limited, but also has to be tested.

Increasing demand for medical devices will also contribute to what I believe would be record profits for Vicplas. Their financial year ends 31 July 2020 - it is a company to watch out for. Its stock price has been rising steadily in the last few months, and a massive breakout is a possibility.

Stockgod39      ( Date: 23-Jul-2020 22:06) Posted:

 
NUS invents new way to produce Covid-19 swab, 40m to be produced in coming months
MON, JUL 13, 2020 - 6:55 PM

[SINGAPORE] National University of Singapore (NUS) researchers have developed a new method of producing nasopharyngeal Covid-19 testing swabs and are preparing to produce 40 million of them in the coming months.

Professor Boey said he believes this makes Singapore the first country in Asia to use 3D-printing to produce swabs and the first in the world to use injection moulding.

A team led by NUS senior vice-president of health innovation and translation  John Eu-Li Wong   Associate Professor Yen Ching-Chiuan, the co-director of the Keio-NUS Connective Ubiquitous Technology for Embodiments Centre   and Professor Jerry Fuh, director of the NUS Centre for Additive Manufacturing developed a 3D-printed swab named Python.

The team worked with Associate Professor David Allen and Professor Wang De Yun from the NUS Yong Loo Lin School of Medicine, researchers from the NUS School of Design and Environment and NUS Faculty of Engineering, and  National University Hospital (NUH) clinicians on the swab' s design, pre-clinical testing and clinical validation.

Another team led by Prof Boey came up with two swab designs, known as IM2 and IM3, that can be produced through injection moulding.

Patents have been filed for the two designs, which are undergoing clinical trials at NUH and Singapore General Hospital.

Prof Boey and his team are now working with four companies - TNC Optics & Technologies, Meiban Group, Inzign, and Forefront Medical - to mass manufacture and sterilise the injection-moulded swabs.

Each manufacturer is estimated to be able to produce 100,000 to 150,000 swabs a day - more than enough for the 40,000 daily tests health officials have said they want to carry out.

https://www.businesstimes.com.sg/consumer/nus-invents-new-way-to-produce-covid-19-swab-40m-to-be-produced-in-coming-months
 


 Useful To Me  Not Useful To Me


Stockgod39
Member
23-Jul-2020 22:13     
 
Stockgod39 About Contact  Quote this Post!  
  x 1
  x 0

 Alert Admin 		Forefront Medical is owned by Vicplas. Not to mention, demand to manufacture such tests will be there for a long, long time because the effectiveness of vaccines is not only limited, but also has to be tested.

Increasing demand for medical devices will also contribute to what I believe would be record profits for Vicplas. Their financial year ends 31 July 2020 - it is a company to watch out for. Its stock price has been rising steadily in the last few months, and a massive breakout is a possibility.

Stockgod39      ( Date: 23-Jul-2020 22:06) Posted:

 
NUS invents new way to produce Covid-19 swab, 40m to be produced in coming months
MON, JUL 13, 2020 - 6:55 PM

[SINGAPORE] National University of Singapore (NUS) researchers have developed a new method of producing nasopharyngeal Covid-19 testing swabs and are preparing to produce 40 million of them in the coming months.

Professor Boey said he believes this makes Singapore the first country in Asia to use 3D-printing to produce swabs and the first in the world to use injection moulding.

A team led by NUS senior vice-president of health innovation and translation  John Eu-Li Wong   Associate Professor Yen Ching-Chiuan, the co-director of the Keio-NUS Connective Ubiquitous Technology for Embodiments Centre   and Professor Jerry Fuh, director of the NUS Centre for Additive Manufacturing developed a 3D-printed swab named Python.

The team worked with Associate Professor David Allen and Professor Wang De Yun from the NUS Yong Loo Lin School of Medicine, researchers from the NUS School of Design and Environment and NUS Faculty of Engineering, and  National University Hospital (NUH) clinicians on the swab' s design, pre-clinical testing and clinical validation.

Another team led by Prof Boey came up with two swab designs, known as IM2 and IM3, that can be produced through injection moulding.

Patents have been filed for the two designs, which are undergoing clinical trials at NUH and Singapore General Hospital.

Prof Boey and his team are now working with four companies - TNC Optics & Technologies, Meiban Group, Inzign, and Forefront Medical - to mass manufacture and sterilise the injection-moulded swabs.

Each manufacturer is estimated to be able to produce 100,000 to 150,000 swabs a day - more than enough for the 40,000 daily tests health officials have said they want to carry out.

https://www.businesstimes.com.sg/consumer/nus-invents-new-way-to-produce-covid-19-swab-40m-to-be-produced-in-coming-months
 

 Useful To Me  Not Useful To Me
Stockgod39
Member
23-Jul-2020 22:06     
 
Stockgod39 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin
 
NUS invents new way to produce Covid-19 swab, 40m to be produced in coming months
MON, JUL 13, 2020 - 6:55 PM

[SINGAPORE] National University of Singapore (NUS) researchers have developed a new method of producing nasopharyngeal Covid-19 testing swabs and are preparing to produce 40 million of them in the coming months.

Professor Boey said he believes this makes Singapore the first country in Asia to use 3D-printing to produce swabs and the first in the world to use injection moulding.

A team led by NUS senior vice-president of health innovation and translation  John Eu-Li Wong   Associate Professor Yen Ching-Chiuan, the co-director of the Keio-NUS Connective Ubiquitous Technology for Embodiments Centre   and Professor Jerry Fuh, director of the NUS Centre for Additive Manufacturing developed a 3D-printed swab named Python.

The team worked with Associate Professor David Allen and Professor Wang De Yun from the NUS Yong Loo Lin School of Medicine, researchers from the NUS School of Design and Environment and NUS Faculty of Engineering, and  National University Hospital (NUH) clinicians on the swab' s design, pre-clinical testing and clinical validation.

Another team led by Prof Boey came up with two swab designs, known as IM2 and IM3, that can be produced through injection moulding.

Patents have been filed for the two designs, which are undergoing clinical trials at NUH and Singapore General Hospital.

Prof Boey and his team are now working with four companies - TNC Optics & Technologies, Meiban Group, Inzign, and Forefront Medical - to mass manufacture and sterilise the injection-moulded swabs.

Each manufacturer is estimated to be able to produce 100,000 to 150,000 swabs a day - more than enough for the 40,000 daily tests health officials have said they want to carry out.

https://www.businesstimes.com.sg/consumer/nus-invents-new-way-to-produce-covid-19-swab-40m-to-be-produced-in-coming-months
 
 Useful To Me  Not Useful To Me
wiltay
Master
22-Jul-2020 12:59     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Fake Q 1000lots @ 0.129 every lunch time..😴 😴 😴 😴
 Useful To Me  Not Useful To Me


wiltay
Master
20-Jul-2020 14:50     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

S' pore to 3D print bulk of 40 million low cost Covid-19 swabs in next few months

Belmont Lay  |    July 20, 2020, 03:54 AM

National University of Singapore (NUS) researchers have made a major breakthrough: They have found a new  low cost way of producing  40 million nasopharyngeal Covid-19 testing swabs  in the next few months  right here in Singapore.
 

This new method would make use of both 3D printing and injection moulding, which is a manufacturing process.

 

Singapore' s reliance on overseas supplies



Currently, Singapore is relying on suppliers from the United States, Italy and other parts of Europe for its swabs.

But there is a global shortage of swabs.

Countries around the world are vying to re-open their economies and are mass testing their respective populations.

 

Two NUS teams working on solution



 

Two teams from NUS have linked up with Temasek Foundation to develop three different swab designs.
his means that Singapore would have the capability and know-how to produce its own swabs.

Singapore is likely the first country in the world to use injection moulding to produce them, and the first in Asia to use 3D printing for this sort of production.

The 3D-printed swab that has been developed is named Python.

The Python swab uses a double helix structure for the tip.

Trials showed this design has good fluid adsorption and causes minimal discomfort to the patient.

 

What are nasopharyngeal swabs?



 

Nasopharyngeal swabs are small, flexible sticks to collect fluid samples from the back of the nasal cavity after it is inserted through the nose.

The tip of the swab has to be specially designed to retain fluid for tests to be accurate.

NUS said Python demonstrated comparable accuracy and performance compared to an industry standard swab when tested on patients with Covid-19.
 

Mass manufacturing in Singapore: Up to 150,000 swabs a day



 

The swab' s design is free for use in Singapore.

Two local companies is mass producing the swab, and a patent has been filed for it.

Another team in NUS came up with two other swab designs, known as IM2 and IM3, that can be produced through injection moulding.

Injection moulding is a faster process than 3D printing, allowing several hundred swabs to be produced in a matter of minutes.

The two designs made by injection moulding are undergoing clinical trials at NUH and Singapore General Hospital.

Patents have been filed for them as well.

Four companies are likely to mass manufacture and sterilise the injection-moulded swabs.

Each manufacturer can produce 100,000 to 150,000 swabs a day.

This is more than enough for the 40,000 daily tests health officials here are aiming to carry out.
 

wiltay      ( Date: 20-Jul-2020 14:45) Posted:


 Useful To Me  Not Useful To Me
wiltay
Master
20-Jul-2020 14:45     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		https://mothership.sg/2020/07/singapore-3d-print-swabs/
 Useful To Me  Not Useful To Me
wiltay
Master
17-Jul-2020 09:56     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		The only thing I dislike about it is This company very low profile and humble 😂 got good news didn't inform investors or publish to public.

lanina1      ( Date: 17-Jul-2020 08:23) Posted:

Their current medical business is at a much better position than few years back when they were making profit. Their customer was too concentrated at that time and that was why their profit slump a lot after their major customer reduced their orders.

wiltay      ( Date: 16-Jul-2020 09:41) Posted:

Ya... I m surprised that their projects related to covid 19😱 . They doing well in medical few years Back.. if I m not wrong.. it getting better lol.. 👍
 Useful To Me  Not Useful To Me
wiltay
Master
17-Jul-2020 09:47     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Hopeful dividend will be better.

lanina1      ( Date: 17-Jul-2020 08:23) Posted:

Their current medical business is at a much better position than few years back when they were making profit. Their customer was too concentrated at that time and that was why their profit slump a lot after their major customer reduced their orders.

wiltay      ( Date: 16-Jul-2020 09:41) Posted:

Ya... I m surprised that their projects related to covid 19😱 . They doing well in medical few years Back.. if I m not wrong.. it getting better lol.. 👍
 Useful To Me  Not Useful To Me


lanina1
Member
17-Jul-2020 08:23     
 
lanina1 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Their current medical business is at a much better position than few years back when they were making profit. Their customer was too concentrated at that time and that was why their profit slump a lot after their major customer reduced their orders.

wiltay      ( Date: 16-Jul-2020 09:41) Posted:

Ya... I m surprised that their projects related to covid 19😱 . They doing well in medical few years Back.. if I m not wrong.. it getting better lol.. 👍

lanina1      ( Date: 16-Jul-2020 09:00) Posted:

This healthcare counter has much better quality rather than the hot cake like medtec biodics etc. Diversified countomer and products, clean balance sheet, clear visibility of profit, very consistant dividend history. 


 Useful To Me  Not Useful To Me
wiltay
Master
16-Jul-2020 14:09     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		news.nus.edu.sg/research/novel-covid-19-swabs-address-shortage

wiltay      ( Date: 16-Jul-2020 14:08) Posted:

--- Post Removed by User ---
 Useful To Me  Not Useful To Me
wiltay
Master
16-Jul-2020 09:41     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Ya... I m surprised that their projects related to covid 19😱 . They doing well in medical few years Back.. if I m not wrong.. it getting better lol.. 👍

lanina1      ( Date: 16-Jul-2020 09:00) Posted:

This healthcare counter has much better quality rather than the hot cake like medtec biodics etc. Diversified countomer and products, clean balance sheet, clear visibility of profit, very consistant dividend history. 

 Useful To Me  Not Useful To Me
lanina1
Member
16-Jul-2020 09:00     
 
lanina1 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin
This healthcare counter has much better quality rather than the hot cake like medtec biodics etc. Diversified countomer and products, clean balance sheet, clear visibility of profit, very consistant dividend history. 
 Useful To Me  Not Useful To Me
wiltay
Master
15-Jul-2020 22:57     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		sorry below is correct one lol..
sgsme.sg/news/diversifying-operations-and-talent-pool-helps-medtech-firm-find-new-income-streams-amid-covid

wiltay      ( Date: 15-Jul-2020 22:48) Posted:

--- Post Removed by User ---
 Useful To Me  Not Useful To Me
wiltay
Master
15-Jul-2020 20:15     
 
wiltay About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		The company that vicplas bought over??? 

johnng      ( Date: 15-Jul-2020 19:09) Posted:

Arrow medical...could be clean room medical technology..long term aim 20cents
 Useful To Me  Not Useful To Me
johnng
Supreme
15-Jul-2020 19:09     
 
johnng About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Arrow medical...could be clean room medical technology..long term aim 20cents
 Useful To Me  Not Useful To Me
josephyeo
Elite
15-Jul-2020 16:35     
 
josephyeo About Contact  Quote this Post! Style: Fundamental  
  x 0
  x 0

 Alert Admin 		Sorry, i have no idea on this coming season dividend payout.
Historically, company had been consistent w its generous dividend.

wiltay      ( Date: 15-Jul-2020 11:26) Posted:

josephyeo.. any chance this coming dividend will be better than previous payout?surprise

josephyeo      ( Date: 14-Jul-2020 22:07) Posted:

Am still holding for long term. Results may be negatively impacted by Covid 19
but fundamentals of the company are good.

Looking forward to next financial results
 Useful To Me  Not Useful To Me
                                                         First   < Newer   1621-1640 of 1738   Older>   Last  



ShareJunction Version: 27 Nov 2020 ver- All Rights Reserved. Copyright ShareJunction Pte. Ltd. Disclaimer: All prices from are delayed. ShareJunction does not provide you with any financial advice. We are not into the business of providing any investment advice. See our Terms and Conditions and Privacy Policy of using this website. Data is delayed for varying periods of time depending on the exchange, but for at least 15 minutes. Copyright © SIX Financial Information Ltd. and its licensors. All Rights reserved. Further distribution and use by third parties prohibited. SIX Financial Information and its licensors make no warranty for information displayed and accept no liability for data and prices. SIX Financial Information reserves the right to adapt and/or alter this website at any time without prior notice.

Web design by FoundationFlux. Hosted with Signetique Cloud.